Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

302.96
+0.22000.07%
Post-market: 302.960.00000.00%19:30 EDT
Volume:179.23K
Turnover:54.44M
Market Cap:6.04B
PE:31.20
High:307.63
Open:307.55
Low:301.32
Close:302.74
52wk High:326.63
52wk Low:175.89
Shares:19.94M
Float Shares:19.35M
Volume Ratio:0.48
T/O Rate:0.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):9.71
EPS(LYR):6.13
ROE:21.96%
ROA:3.99%
PB:6.24
PE(LYR):49.42

Loading ...

Agenus Q2 Revenue Rises on Access and Royalty Income

Reuters
·
Aug 06

GUIDANCE: (LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $9.00 to $9.50, vs. FactSet Est of $9.21

MT Newswires Live
·
Aug 06

Ligand Q2 FY26 Adjusted EPS Climbs 48% to $2.37; Revenue Rises 34% to $63.7 Million

Reuters
·
Aug 06

Ligand Pharmaceuticals Q2 Adj. EPS $2.37 Beats $1.84 Estimate, Sales $63.693M Beat $60.765M Estimate

Benzinga Earnings
·
Aug 06

Ligand Pharmaceuticals Incorporated - 2026 Total Revenue Guidance $270 Mln to $310 Mln

THOMSON REUTERS
·
Aug 06

Ligand Pharmaceuticals Incorporated - 2026 Adj EPS Guidance $9 to $9.50, Previously $8.50 to $9.50

THOMSON REUTERS
·
Aug 06

Ligand Pharmaceuticals Q2 EPS USD 2.22

THOMSON REUTERS
·
Aug 06

Ligand CLO, Secretary Andrew Reardon Reports Disposal of 5,000 Common Shares Worth $1.44 Million

Reuters
·
Aug 05

Ligand Pharmaceuticals Price Target Raised to $326.00/Share from $285.00 by Oppenheimer

Dow Jones
·
Aug 03

Earning Preview: Ligand Pharmaceuticals revenue is expected to increase by 39.69%, and institutional views are positive

Earnings Agent
·
Jul 31

Ligand Pharmaceuticals Price Target Announced at $387.00/share by Citigroup

Dow Jones
·
Jul 22

Ligand Pharmaceuticals Inc : Citigroup Resumes Coverage with Buy Rating; Price Target $387

THOMSON REUTERS
·
Jul 21

Ligand resumed with a Buy at Citi

TIPRANKS
·
Jul 21

Ligand price target raised to $345 from $330 at Craig-Hallum

TIPRANKS
·
Jul 20

Ligand Pharmaceuticals Inc : Benchmark Raises Target Price to $335 from $275

THOMSON REUTERS
·
Jul 16

Ligand Pharmaceuticals is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 16

RBC Capital Adjusts Price Target on Ligand Pharmaceuticals to $340 From $262, Maintains Outperform Rating

MT Newswires Live
·
Jul 15

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Ligand Pharma (LGND)

TIPRANKS
·
Jul 15

XOMA Royalty Corporation Completes Merger with Ligand Pharmaceuticals

TIPRANKS
·
Jul 15

U.S. Research Roundup-equinix, Goldman Sachs, Jpmorgan

Reuters
·
Jul 15